A patient with cystic fibrosis uses inhaled tobramycin TOBI 300 ...

[mynx]

A patient with cystic fibrosis uses inhaled tobramycin TOBI 300 mg every 12 hours in repeating cycles of 4 weeks on and 4 weeks off. The patient reports hoarseness and tinnitus. The nurse will tell the patient that:
 
  a. an intravenous form may be used to avoid hoarseness.
  b. hearing loss may occur with continued use of the drug.
  c. the provider will need to monitor renal function closely.
  d. these are common side effects of this me-dication.

Question 2

A nurse is quizzing a nursing student who is preparing to care for a patient with cystic fibrosis. The patient uses inhaled tobramycin TOBI, dornase alfa Pulmozyme, ibuprofen, and salme-terol Serevent Diskus.
 
  Which statement by the student indicates understanding of this patient's drug regimen? a. Dornase alfa is used as needed to de-crease viscosity of sputum.
  b. Ibuprofen is used to minimize pleuritic pain associated with coughing.
  c. Salmeterol acts by causing bronchodila-tion and improving ciliary function.
  d. Tobramycin is given via a metered-dose inhaler to avoid systemic side effects.

[trampas]

Answer to Question 1

D
Inhaled tobramycin can cause tinnitus but does not cause hearing loss. Hoarseness is a common side effect. An intravenous aminoglycoside can cause hearing loss and is not used chronically for cystic fibrosis. Hearing loss will not occur with inhaled tobramycin. Inhaled tobramycin does not increase the risk of renal toxicity.

Answer to Question 2

Great help.

[mynx]

TY

[trampas]

You're welcome